Q-omics provides the consensus-scored ACTG1P9 profile across patient tissues and cancer cell-line models. ACTG1P9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ACTG1P9 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, ACTG1P9 RNA expression shows 10,244 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight COAD, LIHC, and CCRCC as cancer lineages where ACTG1P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTG1P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTG1P9 survival associations across molecular data types. ACTG1P9 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTG1P9 RNA expression–survival associations across cancer types. High ACTG1P9 expression shows unfavorable associations in PAAD, STAD and LGG, but favorable associations in COAD, KIRC and CESC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify COAD as the clearest survival context for ACTG1P9 RNA expression.
This table summarizes ACTG1P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ACTG1P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTG1P9 shows higher tumor expression in LIHC, COAD, LUAD, BRCA and LUSC. The LIHC box plot shows higher ACTG1P9 RNA expression in tumor versus normal tissue (log2 FC = +0.026, t-test p = .008).
This table shows molecular features associated with ACTG1P9 in patient tissues and cancer cell lines. In patient samples, ACTG1P9 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
